TG Therapeutics Banner Image

TG Therapeutics

  • Ticker TGTX
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
TG Therapeutics Logo Image
  • 11-50 Employees
  • Based in New York City, New York
TG Therapeutics is a biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Currently, the company is developing two therapies targeting hematological malignancies and autoimmune diseases. TG-1101 (ublituximab) is a novel, glycoengineered monoclonal antibody that targets a specific andMore unique epitope on the CD20 antigen found on mature B-lymphocytes.
TG Therapeutics

Most Recent Annual Report

TG Therapeutics MOST RECENT 2019 Annual Report and Form 10K

Report Locked. TG Therapeutics has reached its limit for free report views.

Older/Archived Annual Reports